These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32112927)

  • 1. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches.
    Fan L; Liu C; Hu A; Liang J; Li F; Xiong Y; Mu CF
    Int J Pharm; 2020 Apr; 579():119179. PubMed ID: 32112927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
    El Eit RM; Iskandarani AN; Saliba JL; Jabbour MN; Mahfouz RA; Bitar NM; Ayoubi HR; Zaatari GS; Mahon FX; De Thé HB; Bazarbachi AA; Nasr RR
    Int J Cancer; 2014 Feb; 134(4):988-96. PubMed ID: 23934954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
    Bono S; Dello Sbarba P; Lulli M
    Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
    Goussetis DJ; Gounaris E; Platanias LC
    Autophagy; 2013 Jan; 9(1):93-4. PubMed ID: 23051894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smart Human-Serum-Albumin-As
    Peng Y; Zhao Z; Liu T; Li X; Hu X; Wei X; Zhang X; Tan W
    Angew Chem Int Ed Engl; 2017 Aug; 56(36):10845-10849. PubMed ID: 28686804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
    Mukaida N; Tanabe Y; Baba T
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
    Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
    Wu EJ; Goussetis DJ; Beauchamp E; Kosciuczuk EM; Altman JK; Eklund EA; Platanias LC
    Cancer Biol Ther; 2014 Apr; 15(4):473-8. PubMed ID: 24496081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell Contact with Endothelial Cells Favors the In Vitro Maintenance of Human Chronic Myeloid Leukemia Stem and Progenitor Cells.
    Torres-Barrera P; Moreno-Lorenzana D; Alvarado-Moreno JA; García-Ruiz E; Lagunas C; Mayani H; Chávez-González A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloid leukemia stem cells: cross-talk with the niche].
    Chomel JC; Aggoune D; Sorel N; Turhan AG
    Med Sci (Paris); 2014 Apr; 30(4):452-61. PubMed ID: 24801043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of myeloid leukemias by the bone marrow microenvironment.
    Krause DS; Fulzele K; Catic A; Sun CC; Dombkowski D; Hurley MP; Lezeau S; Attar E; Wu JY; Lin HY; Divieti-Pajevic P; Hasserjian RP; Schipani E; Van Etten RA; Scadden DT
    Nat Med; 2013 Nov; 19(11):1513-7. PubMed ID: 24162813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
    Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
    Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
    Ma W; Liu J; Xie J; Zhang X; Zhou H; Yao H; Zhang W; Guo D; Zhu L; Xiao L; Wu D; Xu H; Chen S; Zhao Y
    J Biomed Nanotechnol; 2015 Nov; 11(11):1961-74. PubMed ID: 26554155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo.
    Wahiduzzaman M; Ota A; Karnan S; Hanamura I; Mizuno S; Kanasugi J; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Takami A; Hosokawa Y
    Cancer Lett; 2018 Oct; 433():117-130. PubMed ID: 29944906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.